Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

SIMPLE SUMMARY: The development of several antiHuman Epidermal Growth Factor Receptor 2 (HER2) treatments over the last few years has improved the landscape of HER2-positive breast cancer. Despite this, relapse is still the main issue in HER2-positive breast cancer. The reasons for therapeutic failu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrando-Díez, Angelica, Felip, Eudald, Pous, Anna, Bergamino Sirven, Milana, Margelí, Mireia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320771/
https://www.ncbi.nlm.nih.gov/pubmed/35884366
http://dx.doi.org/10.3390/cancers14143305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320771/
https://www.ncbi.nlm.nih.gov/pubmed/35884366
http://dx.doi.org/10.3390/cancers14143305

Ejemplares similares